876-88-0

Usage

Uses

Used in Pharmaceutical Industry:
6-bromocinnolin-4-ol is utilized as a pharmaceutical intermediate for its potential anti-tumor properties, making it a valuable component in the development of new cancer treatments. Its bromine atom may enhance the compound's reactivity and interaction with biological targets, contributing to its therapeutic effects.
Used in Medicinal Chemistry Research:
As a brominated cinnolinol derivative, 6-bromocinnolin-4-ol serves as a key subject in medicinal chemistry research. It is studied for its potential to modulate various biological pathways and mechanisms related to tumor growth and inflammation, providing insights into the design of novel therapeutic agents.
Used in Drug Development:
6-bromocinnolin-4-ol is employed as a lead compound in drug development, where its structure can be further optimized to enhance its pharmacological properties. The bromine substitution may offer a unique avenue for chemical modifications, potentially improving the compound's efficacy, selectivity, and safety profile in treating specific diseases.
Used in Materials Science:
The chemical and physical properties conferred by the bromine atom in 6-bromocinnolin-4-ol may also find applications in materials science. Its potential use in the development of new materials with specific properties, such as improved stability or reactivity, could be explored for various industrial applications.

InChI:InChI=1/C8H5BrN2O/c9-5-1-2-7-6(3-5)8(12)4-10-11-7/h1-4H,(H,11,12)

Upstream product

• 20357-04-4 (5-bromo-2-nitro-phenyl)-propiolic acid 
• 624-19-1 4-bromoaniline hydrochloride 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 29124-56-9 1-(2-amino-5-bromophenyl)ethanone 
• 29124-64-9 N-(2-acetyl-4-bromophenyl)acetamide 
• 5234-26-4 N-(2-acetylphenyl)acetamide 
• 551-93-9 2-aminoacetophenone 
• 13631-76-0 (4-bromo-phenylhydrazono)-malonic acid diethyl ester 
• 90271-82-2 (4-bromo-phenylhydrazono)-malonyl chloride 
• 90484-39-2 (4-bromo-phenylhydrazono)-malonic acid 
• 61588-11-2 6-bromo-4-oxo-1,4-dihydro-3-cinnolinecarboxylic acid 

Downstream Products

• 68211-13-2 4,6-dichlorocinnoline 
• 68211-15-4 6-bromo-4-chlorocinnoline 
• 872284-86-1 6-bromo-3-chloro-1H-cinnolin-4-one 
• 1366050-69-2 2-(4-(6-bromo-3-nitrocinnolin-4-ylamino)phenyl)-2-methylpropanenitrile 
• 1366050-70-5 2-(4-(3-amino-6-bromocinnolin-4-ylamino)phenyl)-2-methylpropanenitrile 
• 1366050-29-4 2-(4-(8-(6-amino-5-(trifluoromethyl)pyridin-3-yl)-1H-imidazo[4,5-c]cinnolin-1-yl)phenyl)-2-methylpropanenitrile 
• 1366050-71-6 2-(4-(8-bromo-1H-imidazo[4,5-c]cinnolin-1-yl)phenyl)-2-methylpropanenitrile 
• 552331-97-2 (6-bromo-cinnolin-4-yl)-phenyl-amine 

Relevant academic research and scientific papers

Cnoline compound PI3K kinase inhibitor as well as preparation method and application thereof in pharmacy

The invention provides a cinnoline compound PI3K kinase inhibitor as shown in a formula I. In the cinnoline compound PI3K kinase inhibitor, and R1, R2 and R3 are defined in the specification. The invention also provides a pharmaceutical composition of the

Discovery of cinnoline derivatives as potent PI3K inhibitors with antiproliferative activity

Cinnoline is a potential pharmacophore which has rarely been reported for uses as PI3K inhibitors. In this study, a series of cinnoline derivatives were developed as PI3K inhibitors and evaluated for enzymatic and cellular activities. Most compounds displ

Novel 4-(1H-1,2,3-triazol-4-yl)methoxy)cinnolines as potent antibacterial agents: Synthesis and molecular docking study

A new series of cinnoline-1,2,3-triazole derivatives were designed and synthesized by adopting Cu(1) catalyzed regeoselective1,3-dipolar cycloaddition reaction of terminal alkyne and azide. The in vitro antibacterial activity of all these compounds revealed that compounds 9d, 10a, 10b, and 10c are more potent antibacterial agents. Among the series, compound 4-(3-(4-((cinnolin-4-yloxy)methyl)-1H-1,2,3-triazol-1-yl)propyl)morpholine (10b) exhibited the most potent antibacterial activity against all tested gram-positive and gram-negative bacterial strains. Furthermore, molecular docking studies were also performed to understand the binding interactions of the most active analogs 9d, 10a, 10b, and 10c with Elastase of Pseudomonas aeruginosa (PDB: 1U4G). The results indicated that these classes of compounds have potential antibacterial activity, especially the compound 10b may serve as a promising antibacterial lead compound that could be further optimized for the further development of antibacterial drugs.

Discovery of Pyridopyrimidinones as Potent and Orally Active Dual Inhibitors of PI3K/mTOR

The identification and lead optimization of a series of pyridopyrimidinone derivatives are described as a novel class of efficacious dual PI3K/mTOR inhibitors, resulting in the discovery of 31. Compound 31 exhibited high enzyme activity against PI3K and mTOR, potent suppression of Akt and p70s6k phosphorylation in cell assays, and good pharmacokinetic profile. Furthermore, compound 31 demonstrated in vivo efficacy in a PC-3M tumor xenograft model.

SOMATOSTATIN MODULATORS AND USES THEREOF

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Thiazolidine derivatives or salts thereof as an active ingredient an inhibitor Pim

PROBLEM TO BE SOLVED: To provide compounds which have excellent Pim inhibitory action and are useful as pharmaceuticals.SOLUTION: A compound is a thiazolidine derivative represented by the general formula (1) in the figure, or a salt thereof. (In the formula, X represents O or S; Rrepresents a hydrogen atom or a Calkyl group; Z, Z, Z, Z, Zand Zeach independently represent CH or N; Y represents an optionally substituted, divalent Caromatic hydrocarbon group or the like; Am represents a disubstituted amino group, or an optionally substituted, nitrogen-containing saturated heterocyclic group; and Rand Reach independently represent a hydrogen atom, a halogen atom, an alkyl group or the like.)

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.

PROTOZOAN PARASITE GROWTH INHIBITORS

Compounds and methods for inhibiting growth of a protozoan parasite. Methods of treating a protozoan parasite infection in a subject by administering a therapeutically effective amount of a compound as disclosed herein. The compounds and methods can be us

Discovery of a novel series of thienopyrimidine as highly potent and selective PI3K inhibitors

Inhibition of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway provides a promising new approach for cancer therapy. Through a rational design, a novel series of thienopyrimidine was discovered as highly pote

FUSED HETEROARYLS AND THEIR USES

Provided are certain fused heteroaryls, compositions thereof and methods of use therefor.